Aldeyra Therapeutics Announces Positive Phase 2 Clinical Trial Results and Pipeline Updates

Aldeyra Therapeutics, Inc. announced positive results from a Phase 2 clinical trial in alcohol-associated hepatitis, demonstrating statistically significant improvement in liver function with their investigational drug ADX-629. The company also updated its RASP modulator product candidate pipeline, focusing on next-generation molecules ADX-248 and ADX-246 for dermatologic, metabolic, and retinal immune-mediated diseases. Additionally, Aldeyra extended its projected operational cash runway into the second half of 2027. The company plans to file Investigational New Drug (IND) applications for ADX-248 and ADX-246 in 2026. The clinical development of ADX-629 has been discontinued, pending further investigator-sponsored testing.